The advent of cellular therapies, such as chimeric antigen receptor T-cell therapy, has revolutionized the field of ...

Neoadjuvant chemotherapy's effect on local disease management of breast cancer has a number of clinical implications, including tumor downsizing, potentially improved overall survival, and more.

The FDA granted priority review to taletrectinib in ROS1-positive advanced NSCLC, with a target decision date of June 2025.

Mark Agulnik, MD, discusses the intricacies of desmoid tumors that can be recognized before starting treatment for patients.

Dr. Joshua Sabari discusses the impact that identification of common and rare actionable alterations has had on personalized therapy selection and improved outcomes for patients with NSCLC.